The development of nucleic acid based vaccines against cancer has gained considerable
momentum through the advancement of modern sequencing technologies and on novel …

Cancer immunotherapy aimed at boosting cancer-specific immunoresponses to eradicate
tumor cells has evolved as a new treatment modality. Nanoparticles incorporating antigens …

The primary goal of cancer vaccines is to induce CD8+ T cells specific for tumor-associated
antigens (TAA) but the characterization of these cells has been difficult because of the low …

Immune recognition and elimination of cancerous cells is the primary goal of cancer
immunotherapy. However, obstacles including immune tolerance and tumor-induced …

Chemical conjugation of CTL peptides to tobacco mosaic virus (TMV) has shown promise as
a molecular adjuvant scaffold for augmentation of cellular immune responses to peptide …

Background Experimental cancer vaccines are traditionally administered by injection in
subcutaneous tissue or muscle, commonly with adjuvants that create chronic inflammatory …

Background aims Encouraging evidence of clinical benefits from cancer immunotherapy is
beginning to accumulate in several clinical trials. Cancer immunotherapy is based on two …

Allogeneic hematopoietic cell transplantation (alloHCT) represents the only curative therapy
for several hematologic malignancies, and shows promise as a nascent treatment modality …

Abstract BACKGROUND. E75, a HER‐2/neu‐derived peptide, was administered as a
preventive vaccine with granulocyte‐macrophage–colony‐stimulating factor (GM‐CSF) in …

Minor histocompatibility antigens (mHag) were originally identified as antigens causing graft
rejection or graft‐versus‐host disease in human leukocyte antigen (HLA)‐matched …